/RXRX
RXRX Stock - Recursion Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$4.26-4.05%
$0.18 (-4.05%) • Dec 19
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.11
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.83
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+158.2%upside
Target: $11.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RXRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.22 – $4.30
TARGET (TP)$11.00
STOP LOSS$3.92
RISK/REWARD1:19.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.94
52W High$12.36
52W Low$3.79
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $58.84M | $43.88M | $39.68M | $10.00M | $3.41M |
| Gross Profit | $13.60M | $1.29M | $-8,594,000 | $10.00M | $3.41M |
| Gross Margin | 23.1% | 2.9% | -21.7% | 100.0% | 100.0% |
| Operating Income | $-479,004,000 | $-350,060,000 | $-245,727,000 | $-182,775,000 | $-84,615,000 |
| Net Income | $-463,661,000 | $-328,066,000 | $-239,476,000 | $-186,479,000 | $-87,006,000 |
| Net Margin | -788.0% | -747.7% | -603.5% | -1864.8% | -2549.3% |
| EPS | $-1.69 | $-1.58 | $-1.36 | $-1.05 | $-0.52 |
Company Overview
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
25%
Hold / Neutral
3
75%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
1 Bullish3 Neutral/Bearish
Price Targets
$12
Average Target
↑ 177.8% Upside
Now
$5
Low
$12
Average
$20
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 17th 2025 | JP Morgan | Upgrade | Overweight | $11 |
| July 3rd 2025 | Morgan Stanley | Resumed | Equal Weight | $5 |
| May 22nd 2023 | Morgan Stanley | Initiation | Equal Weight | $8 |
| March 16th 2023 | Needham | Initiation | Buy | $17 |
| September 16th 2022 | KeyBanc Capital Markets | Initiation | Overweight | $20 |
| April 18th 2022 | BofA Securities | Downgrade | Neutral | $10 |
Earnings History & Surprises
RXRXBeat Rate
22%
Last 18 quarters
Avg Surprise
-21.8%
EPS vs Estimate
Beats / Misses
4/11
3 met exactly
Latest EPS
$-0.36
Q4 2025
EPS Surprise History
Q1 24
+13.0%
$-0.40vs$-0.46
Q2 24
+9.3%
$-0.39vs$-0.43
Q3 24
-14.3%
$-0.40vs$-0.35
Q4 24
-3.0%
$-0.34vs$-0.33
Q1 25
-20.5%
$-0.53vs$-0.44
Q2 25
-13.6%
$-0.50vs$-0.44
Q3 25
-17.1%
$-0.41vs$-0.35
Q4 25
+5.3%
$-0.36vs$-0.38
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 27, 2026 | $-0.29 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.38 | $-0.36 | +5.3% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.35 | $-0.41 | -17.1% | ✗ MISS |
Q2 2025 | May 5, 2025 | $-0.44 | $-0.50 | -13.6% | ✗ MISS |
Q1 2025 | Feb 28, 2025 | $-0.44 | $-0.53 | -20.5% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.33 | $-0.34 | -3.0% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.35 | $-0.40 | -14.3% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.43 | $-0.39 | +9.3% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-0.46 | $-0.40 | +13.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.38 | $-0.43 | -13.2% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.38 | $-0.38 | 0.0% | = MET |
Q2 2023 | May 8, 2023 | $-0.34 | $-0.34 | 0.0% | = MET |
Q1 2023 | Feb 27, 2023 | $-0.15 | $-0.31 | -106.7% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.36 | $-0.35 | +2.8% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.35 | $-0.38 | -8.6% | ✗ MISS |
Q2 2022 | May 10, 2022 | $0.51 | $-0.33 | -164.7% | ✗ MISS |
Q1 2022 | Mar 23, 2022 | $-0.30 | $-0.38 | -26.7% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.28 | $-0.28 | 0.0% | = MET |
Q3 2021 | Aug 13, 2021 | $-0.23 | $-0.31 | -34.8% | ✗ MISS |
Latest News
Recursion jumps as J.P. Morgan upgrades on lead program
📈 PositiveSeeking Alpha•Dec 17, 2025, 03:22 PM
Recursion Pharmaceuticals shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $10 to $11.
📈 PositiveBenzinga•Dec 17, 2025, 01:58 PM
JP Morgan Upgrades Recursion Pharmaceuticals to Overweight, Raises Price Target to $11
📈 PositiveBenzinga•Dec 17, 2025, 01:32 PM
Recursion shares are trading higher after the company reported Phase 1b/2 TUPELO results showing REC-4881 reduced polyp burden in FAP, supporting plans for FDA engagement in 1H26.
📈 PositiveBenzinga•Dec 8, 2025, 12:48 PM
Recursion Reports Phase 1b/2 TUPELO Results Showing REC-4881 Rapid And Durable Reductions In Polyp Burden In FAP, Supporting 1H26 FDA Engagement
📈 PositiveBenzinga•Dec 8, 2025, 12:35 PM
Recursion To Present New Clinical Readout From Ongoing TUPELO Phase 1b/2 Trial Of REC-4881 In FAP At Company Webinar On December 8
➖ NeutralBenzinga•Dec 1, 2025, 01:40 PM
Recursion names Najat Khan CEO, succeeding co-founder Chris Gibson; stock down
➖ NeutralSeeking Alpha•Nov 5, 2025, 11:42 AM
Recursion Pharmaceuticals Q3 EPS $(0.36) Misses $(0.31) Estimate, Sales $5.175M Miss $16.983M Estimate
📉 NegativeBenzinga•Nov 5, 2025, 11:35 AM
Recursion Announces CEO Transition As Najat Khan Succeeds Co-Founder Chris Gibson To Lead Next Phase Of TechBio Growth
➖ NeutralBenzinga•Nov 5, 2025, 11:29 AM
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target
📈 PositiveBenzinga•Sep 11, 2025, 11:15 AM
RLYB stock has given up its prior gain. Rallybio shares were trading higher after the company received a $12.5M equity milestone payment from Recursion following the initiation of preclinical studies for REV102.
➖ NeutralBenzinga•Sep 3, 2025, 06:55 PM•Also:
Rallybio shares are trading higher after the company received a $12.5M equity milestone payment from Recursion following the initiation of preclinical studies for REV102.
📈 PositiveBenzinga•Sep 3, 2025, 12:02 PM•Also:
Rallybio Receives $12.5M Equity Milestone Payment From Recursion, Triggered By Initiation Of Preclinical Studies For REV102
📈 PositiveBenzinga•Sep 3, 2025, 12:02 PM•Also:
Recursion to buy Rallybio's ownership in jointly developed bone disorder drug
📈 PositiveSeeking Alpha•Jul 8, 2025, 12:39 PM•Also:
Frequently Asked Questions about RXRX
What is RXRX's current stock price?
Recursion Pharmaceuticals, Inc. (RXRX) is currently trading at $4.26 per share. The stock has moved -4.05% today.
What is the analyst price target for RXRX?
The average analyst price target for RXRX is $11.00, based on 1 analyst.
What sector is Recursion Pharmaceuticals, Inc. in?
Recursion Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is RXRX's market cap?
Recursion Pharmaceuticals, Inc. has a market capitalization of $1.71 billion, making it a small-cap company.
Does RXRX pay dividends?
No, Recursion Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGIO
Agios Pharmaceuticals, Inc.
$24.46
Mkt Cap: $1.4B
BEAM
Beam Therapeutics Inc.
$26.57
Mkt Cap: $2.7B
COGT
Cogent Biosciences, Inc.
$39.55
Mkt Cap: $5.6B
DNLI
Denali Therapeutics Inc.
$16.85
Mkt Cap: $2.5B
ETNB
89bio, Inc.
$14.84
Mkt Cap: $2.2B
GLPG
Galapagos N.V.
$32.36
Mkt Cap: $2.1B
IBRX
ImmunityBio, Inc.
$2.08
Mkt Cap: $2.0B
LQDA
Liquidia Corporation
$34.53
Mkt Cap: $3.0B
RCUS
Arcus Biosciences, Inc.
$21.98
Mkt Cap: $2.4B
SRPT
Sarepta Therapeutics, Inc.
$21.04
Mkt Cap: $2.1B
Explore stocks similar to RXRX for comparison